Dare Bioscience

Dare Bioscience is a clinical-stage biopharmaceutical company focused entirely on advancing health options for women, a segment it regards as historically underserved by the pharmaceutical industry. Headquartered in San Diego, California, the company builds its pipeline around women's sexual and reproductive health, pursuing novel therapeutics and drug-delivery innovations across a range of unmet needs.

The company trades on the Nasdaq Capital Market under the ticker DARE and operates with a specialty focus that distinguishes it from broader-spectrum pharmaceutical developers. Its pipeline has included programmes addressing female sexual dysfunction, contraception, and vaginal health, with particular attention to formulation science as a route to improving tolerability and patient adherence.

Dare Bioscience pursues a partnership-driven development model, collaborating with academic institutions, non-profit organisations, and industry partners to progress its candidates. This approach allows the company to advance multiple programmes concurrently while managing capital deployment, a practical necessity for a company of its size operating in a capital-intensive sector.

The company's emphasis on female-specific indications reflects a broader industry acknowledgement that women's health has been under-represented in drug development pipelines historically. Dare Bioscience positions itself as a dedicated advocate for closing that gap through both its scientific agenda and its public communications.

Further information is available at darebioscience.com.